PhysEmp :: Medicine :: Medical Specialties :: Hematology (7)

All Hematology-Oncology Jobs

Join a strong group in scenic Montana. Beautiful cancer center with state of the art equipment. :: Montana :: CompHealth Inc
Job 917814 Medical Director opportunity for a physician with leadership skills to join a progressive cancer care team. Highly competitive compensation Bonus plan with extra incentives Tumor Board Clinical
Hematology/Medical Oncology in Washington. High income potential and $300K plus the first year! :: Washington :: CompHealth Inc
Job 916966 Beautiful location in the North West. Family community with excellent public and private schools. New state of the art cancer center with top equipment. Strong support staff in a team environment.
Partnership Opportunity for an Oncologist who is looking for a long term practice in Iowa. :: Iowa :: CompHealth Inc
Job 917544 Strong well established practice is seeking a partner to join their growing practice Competitive Compensation in line with MGMA Bonus/ Production Incentives Flexible Schedule Light Call which

Annals of Hematology

Salvage treatment with upfront melphalan 100 mg/m2 and consolidation with novel drugs for fulminant progression of multiple myeloma
Wed, 18 Nov 2009 19:15:05 -0000
Abstract  Patients (pts) with fulminant progression (FPG) of multiple myeloma (MM) after autologous stem cell transplantation (ASCT) have poor prognosis. Pancytopenia, extramedullary disease, and/or renal impairment are often present, and treatment options are limited. We have retrospectively evaluated 31 pts with FPG of MM after ASCT who were treated upfront salvage therapy with melphalan 100 mg/m2 (MEL 100) followed by PBSC support and consolidation therapy using regimens containing thalidomide (n = 16) or bortezomib (n = 15). The overall response rate (ORR) was 58% (18/31). After MEL 100, one patient achieved complete remission (3%), 26% of pts very good partial remission, 29% of pts partial remission, and 42% of pts stable disease. Progression within 3 months after MEL 100 occurred in 35% of pts. The median follow-up from MEL 100 was 8 months. The median TTP was 5 months (range, 2–15 months), and the median OS was 8 months (range, 3–23 months). There were no treatment-related deaths. In fulminant progression of MM, upfront MEL 100 is a safe salvage regimen with good response rate (ORR, 58%). Treatment with upfront MEL 100 followed by a thalidomide- or bortezomib-based regimen can prolong overall survival to more than 12 months in 33% of pts with fulminant progression of MM. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-009-0862-zAuthors Marta Krejci, Masaryk University Hospital Department of Internal Medicine–Hematooncology Jihlavska 20 Brno 625 00 Czech RepublicZdenek Adam, Masaryk University Hospital Department of Internal Medicine–Hematooncology Jihlavska 20 Brno 625 00 Czech RepublicTomas Buchler, Thomayer University Hospital 1st Faculty of Medicine, Department of Oncology Prague Czech RepublicAndrea Krivanova, Masaryk University Hospital Department of Internal Medicine–Hematooncology Jihlavska 20 Brno 625 00 Czech RepublicLudek Pour, Masaryk University Hospital Department of Internal Medicine–Hematooncology Jihlavska 20 Brno 625 00 Czech RepublicLenka Zahradova, Masaryk University Hospital Department of Internal Medicine–Hematooncology Jihlavska 20 Brno 625 00 Czech RepublicMichal Holanek, Masaryk University Hospital Department of Internal Medicine–Hematooncology Jihlavska 20 Brno 625 00 Czech RepublicViera Sandecka, Masaryk University Hospital Department of Internal Medicine–Hematooncology Jihlavska 20 Brno 625 00 Czech RepublicJiri Mayer, Masaryk University Hospital Department of Internal Medicine–Hematooncology Jihlavska 20 Brno 625 00 Czech RepublicJiri Vorlicek, Masaryk University Hospital Department of Internal Medicine–Hematooncology Jihlavska 20 Brno 625 00 Czech RepublicRoman Hajek, Masaryk University Hospital Department of Internal Medicine–Hematooncology Jihlavska 20 Brno 625 00 Czech Republic Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555
Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study
Wed, 18 Nov 2009 00:06:17 -0000
Abstract  The clinical efficacy and safety of a four-drug combination of bortezomib, cyclophosphamide, thalidomide, and dexamethasone was assessed for patients with relapsed or refractory multiple myeloma. Seventy patients received at least two cycles of treatment with bortezomib 1.3 mg/m2 intravenously on days 1, 4, 8, and 11; cyclophosphamide 150 mg/m2 orally on days 1–4; thalidomide 50 mg/day orally every day; and dexamethasone 20 mg/m2 intravenously on days 1, 4, 8, and 11. The overall best response rate was 88%, with 46% complete response, 9% very good partial response, and 33% partial response. After a median follow-up of 12.6 months, the median progression-free survival (PFS) was 14.6 months with a 3-year PFS of 14% and the median overall survival (OS) was 31.6 months with a 3-year OS of 47%. Grade 3 or 4 adverse events included thrombocytopenia (12%), neutropenia (4%), peripheral sensory neuropathy (3%), with thrombosis being very rare (<1%). Bortezomib combined with cyclophosphamide, thalidomide, and dexamethasone is a highly effective salvage therapy with manageable toxicity for patients with relapsed or refractory multiple myeloma. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-009-0856-xAuthors Yeo-Kyeoung Kim, Chonnam National University Medical School Gwangju Republic of KoreaSang-Kyun Sohn, Kyungpook National University Medical School Daegu Republic of KoreaJae-Hoon Lee, Gachon University Incheon Republic of KoreaDeok-Hwan Yang, Chonnam National University Medical School Gwangju Republic of KoreaJoon-Ho Moon, Kyungpook National University Medical School Daegu Republic of KoreaJae-Sook Ahn, Chonnam National University Medical School Gwangju Republic of KoreaHyeoung-Joon Kim, Chonnam National University Medical School Gwangju Republic of KoreaJe-Jung Lee, Chonnam National University Medical School Gwangju Republic of KoreaThe Korean Multiple Myeloma Working Party (KMMWP), Center for Biomedical Human Resources at Chonnam National University The Brain Korea 21 Project Gwangju Republic of Korea Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555
Erratum to: Results of FLT3 mutation screening and correlations with immunophenotyping in 169 Brazilian patients with acute myeloid leukemia
Wed, 18 Nov 2009 00:06:16 -0000
Erratum to: Results of FLT3 mutation screening and correlations with immunophenotyping in 169 Brazilian patients with acute myeloid leukemia Content Type Journal ArticleCategory ErratumDOI 10.1007/s00277-009-0860-1Authors Antonio R. Lucena-Araujo, University of São Paulo Hematology Division, Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, Medical School of Ribeirão Preto Ribeirão Preto BrazilDanielle L. Souza, University of São Paulo Hematology Division, Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, Medical School of Ribeirão Preto Ribeirão Preto BrazilFabio Morato de Oliveira, University of São Paulo Hematology Division, Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, Medical School of Ribeirão Preto Ribeirão Preto BrazilMariana Tereza Lira Benicio, University of São Paulo Hematology Division, Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, Medical School of Ribeirão Preto Ribeirão Preto BrazilLorena L. Figueiredo-Pontes, University of São Paulo Hematology Division, Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, Medical School of Ribeirão Preto Ribeirão Preto BrazilBarbara A. Santana-Lemos, University of São Paulo Hematology Division, Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, Medical School of Ribeirão Preto Ribeirão Preto BrazilGuilherme A. dos Santos, University of São Paulo Hematology Division, Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, Medical School of Ribeirão Preto Ribeirão Preto BrazilRafael H. Jacomo, University of São Paulo Hematology Division, Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, Medical School of Ribeirão Preto Ribeirão Preto BrazilAnemari R. Dinarte-Santos, University of São Paulo Department of Genetics, National Institute of Science and Technology on Cell Based Therapy, Medical School of Ribeirão Preto Av. Bandeirantes, 3900 14048-900 Ribeirão Preto São Paulo BrazilMihoko Yamamoto, Federal University of São Paulo Department of Hematology and Hemotherapy São Paulo BrazilWilson A. Silva-Jr, University of São Paulo Department of Genetics, National Institute of Science and Technology on Cell Based Therapy, Medical School of Ribeirão Preto Av. Bandeirantes, 3900 14048-900 Ribeirão Preto São Paulo BrazilMaria de Lourdes Chauffaille, Federal University of São Paulo Department of Hematology and Hemotherapy São Paulo BrazilEduardo M. Rego, University of São Paulo Hematology Division, Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, Medical School of Ribeirão Preto Ribeirão Preto Brazil Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555

Pediatric Hematology and Oncology: Articles recently published in

HIGH-RISK NEUROBLASTOMA: A Therapy in Evolution
Fong, AbrahamPark, Julie R.
ROLE OF CASPASE 8 AS A DETERMINANT IN TRAIL SENSITIVITY OF NEUROBLASTOMA CELL LINES
Zhang, JinhuaZhang, JihongYang, YanminLu, ChunweiTong, Haixia
HYDROXYUREA-INDUCED HEMATOLOGICAL RESPONSE IN TRANSFUSION-INDEPENDENT BETA-THALASSEMIA INTERMEDIA: Case Series and Review of Literature
Rashidi, ArminZeinali, SyrusBagheri, AlirezaHedayati-Asl, Amir AbbasEhsani, Mohammad Ali

Subscribe to Hematology RSS feed